Chelsea stockholders would receive $6.44 a share in cash and contingent value rights of up to $1.50 a share.
The deal would give H. Lundbeck the rights to Chelsea's drug Northera, which the U.S. Food and Drug Administration recently approved and should release in the third quarter of 2014. The drug treats a rare form of low blood pressure linked to neurological disorders such as Parkinson's disease.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts